Occam Enhances CytomX's Board with Experienced Physician Executive
In March 2024, Occam recruited Zhen Su, MD, to the Board of CytomX Therapeutics, a public clinical-stage biotech in conditionally activated, localized biologics for solid tumors. In January of 2023, the company signed a substantial licensing deal with Moderna.
Su is an accomplished physician executive with nearly thirty years of experience leading oncology research & development and commercial organizations. As the current CEO of Marengo Therapeutics, Su has made significant strides. Under his leadership, the company has expanded its pipeline, progressed its lead asset into clinical trials, and brokered a $1.6B partnership with Ipsen.
Before joining Marengo, Su served as the Senior Vice President and Global Head of the oncology business franchise for Merck KGaA. Previously, he served as the Chief Medical Officer at EMD Serono and held progressively senior leadership positions at Sanofi and GSK.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.